88P Efficacy of olaparib in advanced cancers occurring in patients with germline or somatic tumor mutations in homologous recombination (HR) genes, a Belgian Precision phase II basket study

PARP inhibition with olaparib is a treatment high efficacy in HR deficient cancers that arise carriers of germline mutation the BRCA1/2 genes, particularly ovarian cancer, registered indication. Olaparib also active other related cancers, including breast, prostate and pancreatic cancer. acts through synthetic lethality cancers. responses have however been documented which no mutations were found.